Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.

Kityo C, Boerma RS, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, Boender TS, Mugyenyi PN, Rinke de Wit TF.

J Antimicrob Chemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188.

PMID:
28673027
2.

Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.

Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TFR, Hamers RL.

Lancet Infect Dis. 2016 Nov;16(11):e267-e275. doi: 10.1016/S1473-3099(16)30118-9. Epub 2016 Aug 25.

PMID:
27569762
3.

Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.

Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ.

J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: J Trop Pediatr. 2016 Oct 15;:null.

PMID:
27634175
4.

Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda.

Bajunirwe F, Tumwebaze F, Abongomera G, Akakimpa D, Kityo C, Mugyenyi PN.

BMC Res Notes. 2016 Apr 14;9:217. doi: 10.1186/s13104-016-2024-4.

5.

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.

Kityo C, Sigaloff KC, Sonia Boender T, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugyenyi PN.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11.

6.

Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.

Berry SM, Pezzi HM, Williams ED, Loeb JM, Guckenberger DJ, Lavanway AJ, Puchalski AA, Kityo CM, Mugyenyi PN, Graziano FM, Beebe DJ.

PLoS One. 2015 Dec 2;10(12):e0143631. doi: 10.1371/journal.pone.0143631. eCollection 2015.

7.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team.

J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16.

8.

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.

Parikh SM, Obuku EA, Walker SA, Semeere AS, Auerbach BJ, Hakim JG, Mayanja-Kizza H, Mugyenyi PN, Salata RA, Kityo CM; DART Trial Team.

PLoS One. 2013 Oct 2;8(10):e76158. doi: 10.1371/journal.pone.0076158. eCollection 2013.

9.

Determinants of clinician knowledge on aging and HIV/AIDS: a survey of practitioners and policy makers in Kampala District, Uganda.

Obuku EA, Parikh SM, Nankabirwa V, Kakande NI, Mafigiri DK, Mayanja-Kizza H, Kityo CM, Mugyenyi PN, Salata RA.

PLoS One. 2013;8(2):e57028. doi: 10.1371/journal.pone.0057028. Epub 2013 Feb 28.

10.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.

Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky RP.

AIDS. 2012 Jun 1;26(9):1083-93. doi: 10.1097/QAD.0b013e32835221eb.

11.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team.

N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.

12.

Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy.

Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR.

Int J STD AIDS. 2005 Jan;16(1):38-41.

PMID:
15705271
13.

HIV vaccines: the Uganda experience.

Mugyenyi PN.

Vaccine. 2002 May 6;20(15):1905-8. Review.

PMID:
11983242
14.

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.

Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC; Uganda-Case Western Reserve University Research Collaboration.

AIDS. 2001 Nov 9;15(16):2137-47.

PMID:
11684933
15.

Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration.

Johnson JL, Nyole S, Okwera A, Whalen CC, Nsubuga P, Pekovic V, Huebner R, Wallis RS, Mugyenyi PN, Mugerwa RD, Ellner JJ.

Am J Respir Crit Care Med. 1998 Dec;158(6):1790-6.

PMID:
9847269
16.

Hematological reference ranges among healthy Ugandans.

Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, Mangeni FW, Pattishall K, Katongole-Mbidde E.

Clin Diagn Lab Immunol. 1995 Mar;2(2):233-5.

Supplemental Content

Loading ...
Support Center